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Abstract
Background: Among women at high risk for HIV and other sexually transmitted diseases (STIs), gender and economic
issues limit the impact of behavioral prevention strategies. Women in Kazakhstan with dual risks of sex trading and drug
use face elevated risk for HIV and STIs and may benefit from an economic empowerment intervention which combines
HIV-risk reduction (HIVRR) education with financial skills-building and asset-building to promote reduced reliance on sex
trading for income.
Methods/design: The study employs a two-arm, cluster-randomized controlled trial (c-RCT) design. We will use cluster
randomization to assign 350 women in approximately 50 cohorts to a traditional four-session HIV-risk-reduction
intervention combined with a six-session financial literacy intervention, enrollment in a 24-session vocational
training program and receipt of matched savings (HIVRR+MF); or to the four-session HIV-risk-reduction intervention
alone (HIVRR). Repeated behavioral and biological assessments will be conducted at baseline, then at 6, 9, and 15 months
post randomization/session 1.
Discussion: This study responds to an identified need in the academic literature for rigorous testing of structural
interventions, including combination microfinance and HIV-prevention interventions.
Trial registration: ClinicalTrials.gov, ID: NCT02406482. Registered on 30 March 2015.
Keywords: Women, HIV, STI, Drug use, Microfinance
Background
While the HIV epidemic in Kazakhstan has remained con-
centrated among high-risk populations since its begin-
nings, a recent shift from parenteral to heterosexual
transmission highlights the increased risk of HIV transmis-
sion to, and by, female sex workers (FSW). HIV prevalence
continues to rise among FSW throughout the Central
Asian region, yet there has been limited research and
exposure to evidence-based HIV-prevention interventions
for this population [1]. As of 2014, there were an estimated
19,600 FSW in Kazakhstan, yet only 15 of 93 registered
HIV service non-governmental organizations (NGOs)
throughout the country served FSW [2]. One systematic
review and meta-analysis has estimated that in low- and
middle-income countries like Kazakhstan, sex workers
have 13.5 times the odds of contracting HIV compared to
all women of reproductive age [3]. While official estimates
put the prevalence of HIV among FSW in Kazakhstan at
1.3% [4], HIV prevalence is higher among FSW who use
both injection and non-injection drugs than among FSW
who do not share these additional risks [1]. Drug-using fe-
male sex workers are at the greatest HIV risk and the least
likely to have access to testing, care or treatment services –
they operate at the lower end of the market, are more often
street-based, and are typically much poorer than non-
drug-using FSW [2]. These women’s low social and
economic standing may not only drive entry into sex
work, but may make them financially dependent on pay-
ing or intimate male partners for living and drug expenses,
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less able to negotiate safe sex or safe injection practices,
and may increase their risk for physical or sexual violence
[5–7]. Stigma against both sex work and drug use and ag-
gressive policing may limit their access to health services
including drug treatment as well as legal recourse, and
may subject them to sexual coercion and violence from
police themselves [6, 8]. Furthermore, in Central Asia, few
women who use drugs have been reached through
evidence-based HIV or harm-reduction interventions, and
most local HIV or drug treatment programming has not
met their unique needs [9].
Given how these risks are rooted in women’s low eco-
nomic and financial standing, promoting women’s eco-
nomic empowerment may provide structural protection
from HIV. Structural approaches to HIV prevention are
characterized by Gupta et al. (2008) as those which ad-
dress the physical, social, economic, and policy environ-
ments which create vulnerability to HIV [10]. This
includes programs which seek to alleviate the economic
inequalities faced by high-risk women [11–13]. “Microfi-
nance” has been identified as an important structural
intervention for HIV prevention and improved access to
testing, care, and treatment [13–15]. The term microfi-
nance covers an array of programs and policies, including
financial literacy education, vocational training, condi-
tional or unconditional cash transfers, formal or informal
microcredit or lending, small business development, and
asset-building through savings programs. In Kazakhstan,
microfinance played a crucial role in the establishment of
private enterprise after the fall of the Soviet economic sys-
tem [16]. Microfinance programs usually include a collab-
oration between a banking institution and an NGO or
United Nations agency, offering business guidance such as
product development and marketing in combination with
a microloan [16]. However, we found no microfinance
programs that either target or incorporate drug users or
sex workers. Microfinance lenders may consider these risk
groups too unstable or unreliable for loans, and stigma
against these risk groups may lead to them being over-
looked for other forms of microfinance programming.
There is a small but growing body of empirical studies
done worldwide which have sought to demonstrate the
impact of microfinance interventions on HIV prevention
and care [14, 15, 17–20]. These studies have utilized a
range of the microfinance strategies listed above, either
introducing them individually or in combination with be-
havioral interventions for HIV-risk reduction (HIVRR).
Several studies targeted FSW, including Project JEWEL in
Baltimore, which provided training in craft-making to
FSW who used drugs, and showed, on average, a decrease
in the number of both sexual contacts and paying part-
ners, as well as increased condom use [18]. Through a
similar study in Chennai, India, FSW were taught tailoring
skills, and saw a decrease in paying partners, as well as
increased licit income [19]. A microenterprise interven-
tion with FSW in Kenya’s urban slums, which offered fi-
nancial literacy training and microloans, demonstrated an
overall decrease in the number of sex partners and a
higher consistency of condom use; furthermore, nearly
half of participants stopped sex work altogether and two
thirds developed operational businesses [20].
The majority of microfinance studies included a
microcredit or loan component (both group and individ-
ual loans) to support small business development, or a
vocational training component, but few have focused on
asset-building. The Undarga study among street-based
sex workers in Ulaanbaatar, Mongolia, is the first to have
addressed this, using a randomized controlled trial
(RCT) design to test the efficacy of a savings-led microfi-
nance program in combination with HIVRR [17]. The
benefit of savings-led interventions over microcredit in-
terventions is that they enable participants to accumu-
late assets faster and pay for life events without
accumulating debt and an over-reliance on microloans,
for which interest rates can be onerous. This makes
them less likely to cause additional financial strains for
populations like FSW, which already face significant fi-
nancial burdens. Participants in Undarga were random-
ized to receive either a four-session HIVRR intervention
alone, or the same four-session HIVRR intervention and
a savings-led microfinance program. The microfinance
components included financial literacy training, a busi-
ness development training with mentorship, and a
matched savings program to help women establish small
businesses. Findings showed that women in the microfi-
nance arm reported significantly fewer unprotected sex
acts at 6 months post intervention and that women in
the microfinance arm reported a significantly lower per-
centage of income from sex work, increased odds of
reporting no income from sex work, and increased odds
that sex work was not their main source of income at 6
months post intervention compared to women who re-
ceived HIV prevention alone [17, 21]. While women
from both study arms reported a decrease in the number
of paying sexual partners between the baseline and 6
months post-intervention assessments, those who had
received the microfinance components reported a sig-
nificantly larger decrease than those who received
HIVRR alone [17].
While this study suggests the success of savings-led
microfinance for HIV-risk reduction among FSW, gaps
remain in the evidence base for microfinance for HIV-
risk reduction among women who use drugs. The four
studies detailed above are the only ones which have tar-
geted female sex workers, and only one of these three
targeted FSW who used drugs. Furthermore, past studies
have assessed a limited range of outcomes, mostly self-
reported sexual risk behaviors. No studies to date have
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used biological measures of HIV or other STIs in their
assessments, and only one considered ART adherence as
an outcome. Finally, only a few of these studies utilized
a RCT design.
This paper presents the protocol for a study which
tests a combination HIVRR and savings-led microfi-
nance intervention. The study described here is adapted
from the Undarga study protocol [17]. It responds to
calls for more structural interventions for HIV focused
on women who use drugs [22] and rigorous testing of
HIVRR economic empowerment interventions through
a RCT [13]. To the best of our knowledge, it is the only
study to date to incorporate biological assessments, in-
cluding testing for HIV and other STIs, and viral-load
and CD4 biomarkers for those who are HIV positive. It
is one of the few interventions that focuses on the key
affected population of women at dual risk of HIV from
both drug use and sex work. This study should have glo-
bal as well as regional implications for structural inter-
ventions for HIVRR.
Methods/design
This study uses a cluster randomized controlled trial (c-
RCT) to evaluate a combination HIVRR and microfi-
nance (MF) intervention among FSW who use drugs in
Kazakhstan. The study compares two arms: a combin-
ation HIVRR+MF intervention treatment arm and a
control arm, which receives the HIVRR component
alone. The study assesses outcomes over a 15-month
period, which encompasses up to 3 months of interven-
tion activities, and 12 months of follow-up. Study
recruitment and enrollment began in May 2015, and
follow-up data collection will be completed in October
2018.
The theoretical framework for the study is shown in
Fig. 1. The primary aim of the study is to test whether
participants assigned to the combined HIVRR+MF con-
dition have improved outcomes on a number of indica-
tors, as compared to those assigned to the HIVRR
condition. These indicators include: (1) a lower cumula-
tive incidence of biologically confirmed STIs (syphilis,
gonorrhea, trichomoniasis, chlamydia and mycoplasma),
(2) a lower rate of new HIV and hepatitis C virus (HCV)
cases, (3) a greater decrease in the number of unpro-
tected vaginal and anal sexual acts and a greater increase
in the proportion of protected sexual acts with both
regular and paying partners, (4) a reduction in the pro-
portion of unsafe injection acts for those participants
who inject drugs, and (5) a lower proportion of monthly
income from sex work. These outcomes are summarized
in Table 1.
Secondary aims of the study include an examination of
how study outcomes are moderated by personal and
structural characteristics, including sociodemographics,
substance use history, criminal justice history, sexual
history, etc. Secondary aims also include an examination
of how study outcomes are mediated by several key,
theory-driven variables, such as financial literacy know-
ledge and skills, HIV knowledge, condom use self-
efficacy, se outcome expectancies, etc. In addition, a
qualitative component will examine women’s personal
reactions to each of the HIVRR+MF components, factors
promoting the use of the intervention, and barriers that
may impede their participation and the fidelity of inter-
vention implementation. Finally, a cost-effectiveness
component is included to estimate the costs and cost-
effectiveness of the HIVRR+MF intervention on averted
cumulative STIs, HCV, and HIV over the 12-month
period.
Study setting
This study is being conducted in two cities in
Kazakhstan: Temirtau, and Almaty. These two cities are
geographically distant from one another, with distinct
characteristics. Almaty is the largest city in Kazakhstan
(population 1,703,500) and its economic center [23]. Lo-
cated close to the country’s southern border with
Kyrgyzstan, it attracts both internal and external migrant
workers through trade and job opportunities. Temirtau
(population 181,197) is an industrial city in northern
Kazakhstan [24]. The city is known for high rates of in-
jection drug use in the years following the collapse of
the Soviet Union. This study utilizes a staggered site
start plan; recruitment began in Temirtau in May 2015
Fig. 1 Theoretical framework
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and in Almaty in February 2016. A project field office
was established in each city where both assessment and
intervention activities are conducted.
Participant characteristics
Study participants are women who report recent histor-
ies of both drug use and sex trading. We plan to enroll a
total of 350 women between the two study sites. In order
to be eligible for the study, participants must: (1) be over
18 years old; (2) report illicit drug use within the past 12
months; (3) report having provided sex in return for
money, goods, drugs or services within the past 90 days;
and (4) report at least one incidence of unprotected sex
(with either a paying or non-paying partner) within the
past 90 days. Participants are ineligible if they (1) cannot
communicate in Russian; (2) intend to move from the
study site within the following 12 months, or (3) are
deemed to have cognitive impairment that would affect
their ability to provide consent or participate fully in the
intervention activities.
Intervention
All participants receive four HIVRR sessions and those
assigned to the combination HIVRR+MF treatment arm
receive an additional 30 sessions, including (1) six train-
ing sessions focused on financial literacy, (2) 24 sessions
of vocational training in hairdressing, sewing, or mani-
curist professions, as well as (3) a matched savings pro-
gram which incentivizes them to accumulate assets for
small business development or job/vocational training.
The NOVA intervention period lasts a total of 3 months
post randomization, with intervention activities lasting
Table 1 Assessment variables
Measurement Timepointa
Moderators B M6 M9 M15
Age, income, education, marital status, experience
of sex work, trauma
Sociodemographic Questionnaire X X X X
Substance abuse and criminal justice history Modified Risk Behavior Assessment (RBA) [36] X X X X
Mental health status BSI [37] X X X X
Partner violence history (paying and intimate) Revised Conflict Tactics Scale [38] X X X X
Number and type of sexual partners (past year) Modified RBA [36] X X X X
Perceived stigma Modified Sex Worker Stigma (SWS) Index [39] X X X X
Mediators B M6 M9 M15
HIV/STI knowledge HIV/STI knowledge [40] X X X X
Condom use self-efficacy Condom Use Self-Efficacy Scale [41] X X X X
Condom use outcome expectancies Condom Barriers Scale [42] X X X X
Condom negotiation self-efficacy Condom Negotiation Self Efficacy Scale [43] X X X X
Sexual communication skills Sexual Communication Scale [44] X X X X
Social support MSPSS [45] X X X X
Current partner violence (paying and intimate) Revised Conflict Tactics scale [38] X X X X
Access to services RBA Services [36] X X X X
bFinancial literacy Financial literacy knowledge [46] X X X X
bSavings deposits Bank Statements X X X
bVocational training sessions attended Attendance/process X X X
Outcomes B M6 M9 M15
STI (gonorrhea, syphilis, trichomoniasis, chlamydia,
Mycoplasma genitalium), HCV, and HIV status
Laboratory assays (see Table 2) X X X
Sexual behavioral risk: number and % of unprotected
sexual acts
Modified RBA [36] X X X X
Number and % shared injection acts, other drug use Modified RBA [36] X X X X
Proportion of income from sex work, savings, debt Economic Indicators Questionnaire X X X X
Cost of staff time, supplies, overhead for HIVRR and for MF Project records; Administration review Ongoing
aB baseline (prior to randomization or intervention); M6 month-6 follow-up, M9 month-9 follow-up, M15 month-15 follow-up
bUniquely associated with asset theory and the HIVRR+MF arm
HCV hepatitis C virus, HIV human immunodeficiency virus, HIVRR HIV relative risk, MF microfinance, STI sexually transmitted disease
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for 2 weeks in the control arm, and for the full 3 months
in the treatment arm. A brief description of each inter-
vention component is provided below:
HI- risk reduction (HIVRR)
During the first 2 weeks of the intervention period, both
study arms receive the HIVRR intervention. The HIVRR
intervention was adapted from the Women on the Road
to Health (WORTH) intervention [25]. The CDC identi-
fied WORTH as a best-practice, evidence-based inter-
vention [26] and it has been implemented in a number
of studies in the USA with women who use drugs [25,
27]. We have adapted the core components of WORTH
to meet the cultural context and experience of women
who use drugs and engage in sex work in Kazakhstan.
The HIVRR intervention is guided by social cognitive
theory [28]. It focuses on both sexual and drug use risk
reduction, and is designed to increase communication,
problem-solving skills, and self-efficacy related to safe-
sex behaviors and drug use. Participants explore how
drug use impacts their sexual risk with both paying and
intimate partners, and are trained in communication
skills with both. Role play activities provide the oppor-
tunity for women to practice these skills and to identify
and problem-solve barriers to applying them. Partici-
pants undergo several intimate-partner violence (IPV)
safety planning exercises, and regular check-ins by ses-
sion facilitators ensure that women receive support and
referrals if they feel that their safety is being threatened
by an intimate partner or by another person during the
course of the study. Participants receive basic training in
emergency overdose response skills. Participants discuss
informal and formal support systems available in their
community. Linkage to HIV care, drug treatment (where
available) and other services are provided throughout
their enrollment in the study. Each session has goals
setting and homework assignment that provide the op-
portunity for the women to practice the skills that they
have learned. Participants receive HIVRR in a four-
session intervention delivered twice a week for 2 weeks.
Sessions are conducted in Russian by trained female
facilitators and last for approximately 2 h. Participants
receive small financial incentives (US$12/session) for
sessions attended, as well as small safe-sex kits of
condoms and lubricant.
Financial Literacy Training
During weeks 3 and 4 of the intervention period, the
treatment arm only receives Financial Literacy Training
(FLT). The FLT intervention was adapted from the
financial literacy intervention used in the Undarga
study [17]. FLT sessions focus on facilitating access to
banking services (including how to open an account
and use an ATM card), household budgeting (including
development of a household budget), short- and long-
term savings, debt management and financial negotia-
tions. Sessions are designed to increase participant
knowledge, skills, and self-efficacy related to managing
and controlling finances, which might enhance their
capacity for savings. Participants continue to build
upon the goal-setting skills that they developed in the
HIVRR sessions, and facilitators continue to conduct
safety check-ins. Sessions are held three times per week
over 2 weeks for a total of six sessions. Sessions are
conducted in Russian by trained female facilitators, and
last for approximately 2 h. Participants receive small fi-
nancial incentives (US$12) and safe-sex kits for sessions
attended.
Vocational Training (VT)
During months 2 and 3 of the intervention period, the
treatment arm receives the Vocational Training (VT)
intervention component. VT provides technical educa-
tion and skills-building in a craft or trade. Including VT
as a component in the HIVRR+MF intervention arm al-
lows participants to gain competence in an employable
trade, which grounds the intervention in the real world
for scale-up after the trial ends. Participants in the treat-
ment arm decide whether they wish to be enrolled in
hairdressing, sewing, or manicurist vocational training
sessions (dependent on course availability at each study
site). Our selection of these options was informed by
local feedback and a feasibility pilot conducted prior to
study start, which confirmed that these were considered
growing small business targets for women and that high-
risk women reacted favorably to this model of vocational
training. These trainings are conducted by professionals,
who work either individually in the community or
through a school or training program. VT partner sites
were selected based on the quality of their facilities, the
availability of afternoon and part-time training hours to
accommodate participant schedules, and a reputation
for successful graduation and certifications among stu-
dents. All treatment arm participants are eligible to at-
tend VT sessions regardless of how many FLT sessions
they attended, as the material presented in the VT
sessions is unrelated to the FLT. Vocational training is
provided three times per week over the course of 2
months, for 24 sessions. Tuition is free to participants
and women attend in small groups with only their co-
hort peers. Participants receive small financial incentives
(US$12) for sessions attended.
Matched savings
From week 3 until the end of the intervention period at the
end of month 3, the treatment arm receives the matched
savings component of the intervention. The matched sav-
ings component of the HIVRR+MF intervention is also
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adapted from the Undarga program [17]. Building assets
prior to shifting sources of income or moving to new or
self-employment may increase the likelihood for increased
income from other sources than sex work. As mentioned
above, participants receive incentive payments (US$12/ses-
sion) for each FLT or VT session attended. During the FLT
intervention, participants receive support to open a per-
sonal savings account in a partner bank, and are encour-
aged to deposit their session attendance incentives in this
account. Throughout the rest of the treatment intervention
period, for every dollar of their incentive payment money
deposited in their personal account, the project will deposit
an equal amount in a separate, project-controlled account
under the participant’s name. Participant’s funds will only
be matched up to the total amount that they have received
from incentive payments for session attendance – this limit
ensures that women are not earning income through sex
work for their matched savings. If a participant decides to
save 100% of her incentive after every session, she will have
saved a total of US$360 and would receive a matching
US$360 for a total of US$720. Due to lack of documenta-
tion, lingering distrust of the banking system, or other bar-
riers, some women may elect to never open a bank
account. These participants have the option to store money
with the program staff in an informal account until the
time of withdrawal, and these informal accounts are also
matched in a separate, project-controlled account under
the participant’s name.
For a duration of 6 months after the duration of
intervention sessions (until the month-9 follow-up as-
sessment) participants may use matched savings
amounts to pay for business or education expenses, in-
cluding equipment and supplies for hairdressing, sew-
ing, or manicurist professions (e.g., rental of a chair in
a salon, products, fabric, sewing machines, etc.) or
additional training (e.g., extra course fees). FLT inter-
vention facilitators conduct a final “transitional ses-
sion” at the end of the vocational training courses
where participants are asked to set long-term goals re-
garding their chosen profession, and plan for spending
their accrued matched savings. FLT intervention facili-
tators work with each participant to identify ways in
which she can spend her matched savings. When a
participant is ready to make a vocation-related pur-
chase, she must provide half the amount of this pur-
chase from her personal savings. The other half the
amount of the purchase is provided by project staff
from the participant’s matched account directly to the
vendor or educational establishment. In order to re-
ceive this 1:1 match on their purchases, participants
are required to make these purchases within 6 months
of completing their vocational training (until their
month-9 follow-up assessment); after this time, the
project will not provide half the payment.
Retention sessions for control participants
As the treatment arm spends approximately 10 weeks
more in the intervention sessions than the control arm,
we utilize retention visits among the control cohorts to
minimize a potential attentional-effect bias in favor of
the treatment groups. These retention visits occur once
a month for 3 months following the HIVRR interven-
tion. Control arm participants are invited back to the
field office together as a cohort, to receive small gifts
(phone cards and toiletries) and to provide updated con-
tact information to project staff. No additional training
or intervention activities are provided at these retention
visits, but participants are given the opportunity to inter-
act with one another and discuss the content of the
HIVRR sessions.
Intervention facilitators and supervision
The HIVRR and FLT sessions are led by trained study fa-
cilitators, supervised by study staff and investigators. A
number of quality assurance measures have been put
into place to ensure standardization across sessions and
facilitators. Facilitators complete session evaluation
forms after each session. Sessions are audio-recorded,
and tapes are randomly selected for review by local clin-
ical supervisors and US-based study investigators. Clin-
ical supervisors note adherence to the intervention
protocol and address any areas of immediate concern
directly with the facilitators. Team supervision is held
once a month with US-based study investigators through
Skype calls to discuss the challenges faced by facilitators
in conducting the sessions and adhering to the protocol.
Study procedures
The study design is summarized in the Consolidated
Standards of Reporting Trials (CONSORT) diagram
(Fig. 2) and in the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) schedule (Fig. 3
and Additional file 1). We expect to enroll 350 partici-
pants in the intervention over the course of 2 years, and
to follow them up over 15 months post randomization.
Prior studies in Kazakhstan have yielded retention rates
of 88% [29]; we expect to retain 80% (n = 280) of partici-
pants at their month-15 follow-up assessment.
Start-up phase activities
During the start-up phase of the study, study research
assistants identified a number of field locations from
which to recruit potential participants. These included
hotels, saunas, and other locations where sexual services
are known to be offered, medical organizations such as
local AIDS centers and drug treatment clinics, and
NGOs providing HIV support or social services to
women. Research assistants observed these sites to un-
cover patterns in availability of potential participants,
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dependent on season, day of the week, holidays, etc.
During this exploratory phase, they also noted
community-based “gatekeepers” who control access to
potential sex workers. These not only included the
NGOs and outreach workers who were our collaborating
partners, but also those who manage sex work transac-
tions in the community. While we discovered that there
are very few formal “pimps” or “madams” who run offi-
cial sex work establishments, sex workers in Kazakhstan
often work through local hotel and sauna administrators,
who direct clients to them. Research assistants described
the study to these gatekeepers as a project meant to im-
prove the health of sex workers, emphasizing the bene-
fits of HIV and STI testing that it would provide, and
asked for their help in referring potential participants
when recruitment began. The relationships established
through this phase reduced resistance and uncertainty
from these community gatekeepers, easing later recruit-
ment efforts.
Recruitment and screening
This study utilizes two channels of participant recruit-
ment: field recruitment visits by research assistants, and
network-based recruitment through a peer-referral pro-
gram. Research assistants conduct regular visits to
NGOs, HIV clinics, drug treatment clinics, hotels,
saunas and street-based sex work venues, where they ap-
proach potential participants, provide them with a brief
overview of the intervention, and then ask for their ver-
bal consent to conduct a screening for study eligibility.
To extend recruitment deeper into communities of
FSW, eligible participants receive a small financial
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) flow diagram
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incentive (US$5) to refer their friends and acquaintances
to be screened for the study. This is done through a sys-
tem of paper coupons. The referred network members
contact the project staff and come to the project field of-
fice location at their convenience to complete screening.
A computerized survey tool is used for eligibility screen-
ing procedures. Research assistants read the computerized
questionnaire aloud to participants, asking them a number
of demographic and risk-behavior questions, including
those described in the eligibility section above. Partici-
pants are compensated US$1 for their time. The survey
tool automatically calculates whether participants are eli-
gible based on the responses entered by the research as-
sistant. If participants are not eligible for any reason, they
are invited to be screened again after 90 days have passed.
Eligible participants are scheduled for study intake
procedures and the baseline assessment (described
below) at the project field office location as soon as pos-
sible after the screening. During this baseline visit,
research assistants describe the details of the study to
potential participants and lead them through an
informed consent process.
Research staff enroll each participant into an interven-
tion cohort within 2 weeks of their baseline. If more
than a month has passed between the participant’s base-
line survey and the start of the intervention session, the
participant is re-screened to confirm continued eligibil-
ity, and baseline assessments are conducted again to
collect more recent data.
Group assignment and randomization
We enrolled participants into groups of six to eight par-
ticipants each, then randomized and followed them as a
cohort over time. Together as a cohort, participants are
randomized to either the treatment (HIVRR+MF) or
control (HIVRR) condition at the time of the first inter-
vention session. Randomizing by cohort is more efficient
than attempting to accrue enough women in a short
enough period to randomize individually and simultan-
eously to two conditions. A random-number generator
randomly assigned each cohort of participants to either
the treatment or control condition. This random num-
ber generator ensured a balanced assignment of cohorts
to each arm over time. Neither participants nor study
staff are blind to study condition.
Process measures
In addition to the intervention quality control measures
described above, a number of process evaluation mea-
sures are collected by the study staff to ensure fidelity
and standardized delivery of study components among
participants and between two diverse study sites. Among
the process evaluation measures included are interven-
tion session attendance (for both treatment and control
arms), vocational training attendance (for treatment
arm) and matched savings deposits and spending (for
treatment arm), and retention measures. These process
measures are used for a number of reasons, including
supervision, assessment of standardization and fidelity to
Fig. 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schedule
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the intervention, and for use in booster training events
throughout the study period.
Assessments
Baseline and follow-up assessments are administered by
research assistants in project field office locations. Assess-
ments take place at a pre-intervention baseline (prior to
cohort assignment and randomization), then at 6, 9, and
15 months after randomization and intervention session 1
(which occur simultaneously, as participants are random-
ized as a cohort immediately prior to beginning the first
intervention session). Since the HIVRR+MF treatment
arm receives an intervention that is approximately 2.5
months longer than the control arm, we allocated an add-
itional 2.5 months of follow-up time for in the control
arm. Behavioral questionnaires are utilized at all assess-
ments, and biological testing procedures are conducted at
baseline, month-9 and month-15 assessments.
Behavioral questionnaires are conducted using computer-
assisted self-interviewing (CASI) methods, with the same
survey tool that the research assistants use to assess study
eligibility and which can be completed in approximately 2
h. The baseline behavioral questionnaire addresses the main
outcome variables of interest to the study (number of part-
ners, number of sex acts, number of sex acts which are un-
protected, number of paying partners, incidences of drug
use, incidences of injection drug use and incidences of risky
injection behaviors) in addition to several of the theoretical
constructs underlying the study (self-efficacy in a number
of risk-reduction behaviors, outcome expectancies and risk-
reduction intentions) and a number of potential moderators
(demographics, financial status, experience of IPV and
gender-based violence (GBV), social support, linkage to
care and service utilization). Table 1 contains a list of the
specific measures used for each construct.
Follow-up assessments occur as early as 1 week before
the exact follow-up date, and as late as 3 weeks after the
exact follow-up date. Like the baseline behavioral ques-
tionnaire, the follow-up behavioral questionnaires ad-
dress the main outcome variables, moderators and
mediators of interest to the study. The follow-up ques-
tionnaires also include additional questions to assess
how HIVRR+MF participants have utilized the voca-
tional training and financial literacy training that they
have received.
To complement self-reports and utilize an objective
assessment measure of risk behavior, we use biological as-
says to confirm HIV and STI status. We selected five STIs:
syphilis, gonorrhea, chlamydia, trichomoniasis and myco-
plasma as objective proxies of sexual risk behavior. The
choice of these STIs was based on their high prevalence
and incidence in this population and the availability of de-
finitive treatment with a single-dose medication (which ob-
viates STI medication treatment adherence and compliance
issues). We also selected HCV to index drug-related risk
behaviors. A clinical coordinator conducts biological testing
in each project field office location. A complete description
of test systems used is provided in Table 2.
Participants who test positive for any STI are provided
with referrals and treatment. The clinical coordinator
works with individual participants to ensure that they
complete their course of treatment prior to randomization
and session 1, ensuring that any STI acquired post
randomization is an incidence STI, and, as soon as pos-
sible at follow-up, biotesting assessments. STIs acquired
and treated between the baseline and month-9 assessment
or between the month-9 and month-15 assessment at an
external clinic are only included as an endpoint if it is self-
reported by participants on their month-9 and month-15
assessments. The clinical coordinator refers participants
who screen positive for syphilis to the local Skin and Ven-
ereal Disease Dispensary to receive additional confirma-
tory testing for syphilis, consultations with a physician,
and treatment for active forms of syphilis. Treatment for
HCV is not widely available in Kazakhstan, and clinical
coordinators refer participants who test positive for HCV
to specialized clinics for additional examination, monitor-
ing, and treatment. Treatment for HIV is also limited in
Kazakhstan. If participants receive a positive rapid test for
HIV, the clinical coordinator refers them to the local AIDS
center for confirmatory testing and treatment. HIV-
positive participants sign an additional waiver allowing
our study access to treatment records at the local HIV
clinic. Clinical coordinators collect information on con-
firmatory testing (for newly diagnosed cases of HIV),
viral-load test results, CD4 test results, and antiretroviral
(ARV) medication history at every assessment period for
each participant.
Participants receive the equivalent of US$10 for the
baseline assessment, US$9 for the month-6 follow-up as-
sessment, US$11 for the month-9 follow-up assessment,
and US$16 for the month-15 follow-up assessment. The
total possible reimbursements for assessments is US$46.
Qualitative assessment
To help us open the “black box” of HIVRR+MF delivery,
we conduct semi-structured, in-depth interviews at three
points in time during study implementation: at 1 month,
3 months and 15 months post randomization and ses-
sion 1 (corresponding to the end of the financial literacy
sessions, vocational trainings sessions for HIVRR+MF
participants, and to the month-15 follow-up assessment
for all participants). We randomly select one participant
from each cohort (approximately 50 women) to
complete interviews. Questions focus on participants’
perception of the intervention, their experience with
both the HIV-risk reduction and microfinance compo-
nents and their reaction to the various role-plays,
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activities and goal-setting assignments, as well as the re-
actions or interactions with family, friends, colleagues
related to their participation, factors promoting the use
of the session information and skills and barriers imped-
ing participation. Importantly, questions also focus on
perceptions of how the intervention influenced partici-
pant safety, including any policy involvement, stigma or
discrimination, drug use before and during the interven-
tion, and savings and the potential access to matched
savings, and alternative income sources. All interviews
are audio-taped, transcribed and translated to English.
Cost-effectiveness is measured through a series of staff
questionnaires, asking project staff about the time they
spend on various intervention activities, along with bud-
gets and financial records.
Data analysis
In assessing primary outcomes (STI, HIV, and HCV inci-
dence, unprotected sexual acts and unsafe injection acts),
our over-arching modeling approach estimates interven-
tion differences (HIVRR alone versus HIVRR+MF) longitu-
dinally using a generalized estimating equations (GEE)
approach, a flexible extension of conventional regression
models, to account for repeated measures and clustering
imposed by randomizing individuals in groups of six to
eight women per cohort. STIs will be summarized as both
a count (number of positive test results for any of the five
STIs of interest (syphilis, gonorrhea, chlamydia, tricho-
moniasis, mycoplasma)) over the entire follow-up period,
as well as a binary indicator of a positive test for any STI of
interest at each follow-up time. The primary analysis will
be a logistic GEE (e.g., presence/absence of an incident STI
post randomization), accounting for clustering imposed by
the study design in having women receiving their random-
ized intervention in cohorts of six to eight women each.
Additionally, secondary analyses will consider intervention
effects on HIV and HCV incidence as operationalized by
binary indicators of testing positive for either, respectively,
over the entire follow-up. We will employ logistic (binary
outcomes) and Poisson (count outcomes) GEE models to
estimate intervention effects as appropriate. We will imple-
ment an intent-to-treat approach for all analyses. Model
estimates will be presented as estimates of incidence risk
ratios or odds ratios, as appropriate, and corresponding
95% confidence intervals (CIs) and p values will be calcu-
lated for inference. Additionally, a logistic GEE modeling
approach will be implemented for dichotomous outcomes
(e.g., GEE with specified logit link) when evaluating the fol-
lowing outcomes: (1) self-reported unprotected vaginal and
anal sexual acts with both regular and paying partners and
(2) self-reported unsafe injection acts. Again, we will be in-
terested in estimate rate ratios or odds ratios comparing
HIVRR+MF to HIVRR alone. A Poisson GEE modeling
strategy (e.g., GEE with specified log link) will be imple-
mented to evaluate remaining secondary outcomes (1) self-
reported number of unprotected vaginal and anal sexual
acts with both regular and paying partners and (2) self-
reported number of unsafe injection acts. To evaluate the
secondary aims of the study related to potential moderat-
ing effects, we will expand these models to include “moder-
ator X intervention” interaction terms along with the
corresponding main effects and will assess examine the sig-
nificance of each moderator on intervention effects
through these interaction terms.
To examine whether key, theory-driven variables me-
diate the intervention’s effects on the primary outcomes,
Table 2 Biotesting systems used
Infection Testing specimen Test system used Sensitivity (95% CIa) Specificity (95% CIa)
HIV Finger stick (whole
blood sample)
Alere Determine™ HIV-1/2 Ag/Ab Combo
rapid test system [47]
99.9% (99.4–100.0%) 99.8% (99.5–99.9%)
Hepatitis C
(HCV)
Dried blood spot Murex anti-HCV (version 4.0) [48] 100% (94.79-100%) 99.88% (99.77–99.94%)
Syphilis Dried blood spot Murex ICE Syphilis [49] 100% (99.1–100%) 100% (99.2–100%)








Chlamydia Vaginal specimen AmpliSense N. gonorrhea/C. trahomatis/
M. genitalium/T. vaginalis-MULTIPRIME-
FRT PCR [50]
100% (73.3–100%) 100% (98.1–- 100%)
Mycoplasma
genitalium
Vaginal specimen AmpliSense N. gonorrhea/C. trahomatis/
M. genitalium/T. vaginalis-MULTIPRIME-
FRT PCR [50]
76.5% (50.1–93.0%) 100% (98.1–100%)
aCI confidence interval
bN/A estimates are not available for vaginal specimen samples
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again we expand the logistic GEE modeling framework
from the primary aim to examine (1) whether the
HIVRR+MF improves the primary outcome compared
to HIVRR alone; (2) whether the intervention improves
each mediator; and (3) whether improvements in the
mediator over time are associated with improvements in
the primary outcome over time.
Power and sample size
Power and sample size considerations for this proposal pri-
oritized sufficiently powering the study to detect interven-
tion effects on incidence for the following biological
outcomes: STIs (syphilis, gonorrhea, trichomoniasis, chla-
mydia, and mycoplasma), HIV and hepatitis C virus (HCV).
Using baseline prevalence estimates from our prior work in
similar populations (e.g., 10%, 28%, and 75%, for STIs, HIV,
and HCV, respectively) [29], we conservatively focused on
the least prevalent of the three biological outcomes of inter-
est, STIs. We noted that if we were sufficiently powered to
estimate intervention efficacy for the least prevalent out-
comes, we would also be sufficiently powered to detect
intervention effects for the others. Using these prevalence
estimates, we determined a range of plausible incidences
based on our experience in similar settings. We first calcu-
lated crude (unadjusted for clustering by cohort) using a
conventional approach to detect differences in a binary out-
come (e.g., incidence) in two groups assuming an α-level of
0.05 for a two-sided hypothesis test of an overall interven-
tion effect. Crude sample size estimates were then inflated
by the “variance inflation factor” as described in Donner
and Klar [30], to account for the likely correlation of out-
comes induced by the study’s cluster randomized design. Fi-
nally, we adjusted 20% attrition over the 15-month follow-
up. We considered scenarios of modest (intraclass cluster-
ing coefficient (ICC) equal to 0.005) and moderate (ICC =
0.01) clustering effects. In summary, we determined that
randomizing 350 women in equal proportions to each
intervention (175 to HIVRR and HIVRR+MF) would en-
sure that 80% power to detect true relative risks of 0.25 and
ICC = 0.01. This attrition and clustering adjusted sample
size corresponds to detecting STI incidence relative risks
(RR) equal to 0.25 comparing women randomized to
HIVRR+MF to HIVRR alone, where the assumed STI inci-
dence over the study follow-up period is 0.043 and 0.144,
respectively. In these calculations, the assumed incidence in
HIVRR alone of 0.144 represents a decrease of approxi-
mately 40% from the estimated baseline prevalence of 28%
from our prior work in this population [29]. Because the
other biological outcomes of interest are more prevalent,
we expect to have greater than 80% power to detect similar
intervention effects.
Qualitative analyses
Data from the in-depth interviews will be transcribed and
translated prior to content analysis. Content analyses will
identify emergent themes related to participants’ experi-
ences with the intervention components that each re-
ceived, how they utilized the skills learned in the
intervention, and the impact that participation in the
intervention had on their lives. Data will be analyzed using
NVivo software, aided by group discussions to reach con-
sensus on themes identified.
Cost-effectiveness analyses
Cost-effectiveness of the intervention will be analyzed
based on STI infections and number of HIV and HCV
cases averted over the 12-month period. We will com-
pare cost-effectiveness of HIVRR+MF to HIVRR, using
the cost of staff time, supplies, and overhead for the
HIVRR and the MF interventions. We will calculate the
incremental cost-effectiveness ratio between treatment i
(HIVRR + MF) and j (HIVRR) in terms of outcome k by
comparing extra cost with extra effectiveness in paired
combinations: ICERijk = (Ci – Cj)/(Eik – Ejk) where Ci
and Cj are the costs and Eik and Ejk are the effectiveness
measures for treatments i and j measured along output
k. This approach safeguards validity against any biased
measurements of cost or effectiveness that are common
to both i and j because they cancel out. Policymakers
can easily and directly compare ICERijk to their existing
costs and cost-effectiveness metrics to assess the added
benefit of the microfinance intervention. We will also re-
port total cost-effectiveness ratios for each intervention:
CERik = Ci/Eik. To construct an effectiveness outcome
of HIV, STIs, and HCV transmissions averted, we will
use standard modeling procedures reported in HIV cost-
effectiveness literature; i.e., a Bernoulli Process Model,
the difference in risk-behavior frequencies times HIV
transmission probabilities per act [31, 32]. One-way sen-
sitivity analyses will use a range (e.g., 95% CIs) of HIV
and HCV rates in the target population that may be
compared to results to assess the robustness of esti-
mates. Policymakers may compare the HIV, STIs, and
HCV cost-effectiveness ratio to ratios for existing HIV
interventions [31, 32] to ascertain the potential value of
the microfinance intervention.
Quality assurance and fidelity
Standardized protocols and trainings are used to assure
consistency and fidelity to the intervention and assess-
ments across multiple study sites. Research assistants, clin-
ical coordinators, and facilitators receive standard training
in their areas of responsibility, including procedural man-
uals and checklists. The use of CASI for baseline and
follow-up behavioral assessments ensures that each partici-
pant is receiving the same version of the questionnaire,
and that there is no response bias. Each site receives daily
supervision from a site coordinator, who is responsible for
reviewing study records and reporting any irregularities or
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protocol violations to the study team. Data management
staff on the study team are responsible for coordinating
data collection across multiple databases. Weekly Skype
meetings with study investigators are used to address any
issues or challenges.
A Data Safety and Monitoring Board (DSMB), consist-
ing of Kazakhstan-based researchers, has been identified
and meets on an annual basis to review all ongoing
study data and human subjects issues.
Discussion
This paper describes the protocol for implementing a com-
bination HIV-risk reduction and savings-led microfinance
intervention, conducted among high-risk women in
Kazakhstan. This clinical trial has a number of strengths,
including its understudied and underserved target popula-
tion of women who both use drugs and engage in sex trad-
ing for drugs and money, its selection of a combination
HIVRR and a savings-led microfinance intervention as a
structural intervention for these women, and the imple-
mentation of this intervention through a rigorous study
design.
As we have described above, the specific target popula-
tion of our intervention has been largely absent in past
HIV-risk-reduction interventions. While combination
HIVRR and microfinance interventions have been shown
to reduce HIV risk and empower women to protect
themselves, these studies rarely focus on women who
use or inject drugs. Both our intervention and our as-
sessments are tailored to the needs and realities of
women who share the dual risks of sex work and drug
use. HIVRR intervention sessions carefully incorporated
core components of the intersection of drug use and
sexual risk, and risk-reduction strategies with paying
partners. We also structured the behavioral question-
naires to address constructs that have never been scien-
tifically evaluated among this high-risk group in
Kazakhstan; e.g., experience of violence by FSW [2].
The intervention presented in this study is one of the
few which has combined HIVRR with savings-led microfi-
nance, and the only one to do so among this target popula-
tion. This trial, therefore, meets the call for more structural
interventions for HIVRR which are designed for women
who use drugs [22] and who sell sex [33]. The HIVRR
intervention sessions not only address women’s behavioral
risks for HIV, but also the complex risk environment faced
by our participants, through overdose response training,
service referrals and safety planning. The microfinance
component of the program further builds on these risk en-
vironment elements by addressing women’s economic em-
powerment. The selection of a savings-led microfinance
was based on the limitations that microcredit and micro-
loan programs pose [34]. Our savings-led approach enables
participants to accumulate assets faster and pay for life-
cycle events without accumulating debt and an overreli-
ance on microloans.
Finally, our study addresses many of the scientific limi-
tations of previous studies.
Ours is the first RCT conducted with FSW in
Kazakhstan, and one of the few conducted in Central Asia.
Our use of a longitudinal study design, assessing outcomes
over a 12-month post-intervention period, allows for us to
examine the long-lasting effects of our intervention and
assess the sustainability of its outcomes. Our mixed-
methods approach, which includes biological assessments,
behavioral questionnaires, in-depth interviews, and cost
data, allows us to assess the impact of our intervention on
multiple levels. The qualitative component of our study
uses in-depth interviews to probe deeper into the barriers
to savings and vocational entry experienced by FSW, as
well as providing information on the feasibility and ac-
ceptability of the intervention.
Academic literature on microfinance for HIV-risk re-
duction has called for a more rigorous testing of inter-
ventions, examination of the causal pathways between
microfinance and reduced risk-behavior outcomes, and
the use of biomarkers [12, 14]. Our assessments provide
much-needed data on the experiences, risks and needs
of this population in Kazakhstan, the variables that mod-
erate and mediate HIV-risk outcomes, and how these
differ between treatment and control conditions. We are
the first study, to our knowledge, to use biological test-
ing to supplement self-reported HIV and STI data. Our
stringent quality control measures and the use of a com-
puterized data collection tool ensure standardization and
consistency among participants.
Challenges and limitations
Our study design uses several tools for reducing biases.
Cluster randomization methods may offset the effects of
selection bias, and analyses will compare baseline char-
acteristics of both treatment and control arms. Our as-
sessment measures include sensitive information on
highly stigmatized behaviors, including sexual behavior
history and drug use. We recognize the risk of reporting
bias in these assessments, and have taken measures to
minimize the risk of this, including establishing trust
through the informed consent process and the use of
CASI, which allows participants privacy and anonymity
as they complete the survey measures. Finally, given the
long time frame of our study and the staggered start
dates between the Temirtau and Almaty sites, we sus-
pect that external confounding factors may influence
participant enrollment and intervention outcomes. For
example, we have already observed a rapid contraction
of Kazakhstan’s economy and a currency devaluation in
the summer of 2015, which may impact participants’ sav-
ings behavior.
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We expect several challenges in recruitment and re-
tention of participants. FSW who use drugs are highly
marginalized, and often hesitant to seek healthcare and
other services for fear of stigma or legal repercussions
[5]. Our decision to recruit at field locations as well as
through a peer-referral system was intended to extend
the reach of our study to as many FSW as possible.
However, there is some evidence that shows that
network-based recruitment and venue-based recruit-
ment of FSW yields populations with different sociode-
mographic characteristics and even different STI
prevalence [35]. We aim to resolve this issue through
random assignment to study condition, and to conduct
analyses that consider recruitment source, and any other
differences potentially identified between study condi-
tions, as a moderating variable.
We have instituted a number of strategies to address
potential loss to follow-up of participants. Past studies
have found that up to 80% of FSW move between cities
[2], and our selection of Almaty as a study site, a border
town with high rates of migration and mobility, suggests
that attendance at follow-up recruitment may be low.
We have tried to preemptively address this problem
through: a month-long follow-up window, which allows
for maximum flexibility, the collection of exhaustive
contact information for each participant; the use of re-
tention visits for control cohorts to maintain contact
during their longer post-intervention period prior to the
first follow-up; and through the creation of a supportive
and pleasant office and intervention group atmosphere,
which, we hope, will encourage women to return.
Implication of this study in HIV prevention
Our study examines the benefits of investment in
income-generating interventions as an HIV prevention
strategy among high risk women. If successful, it may re-
move some of the hesitations and stigma that prevent
investment in economic opportunities for women who
use drugs or who sell sex. We hope that this interven-
tion model will demonstrate that HIV prevention for
women who use drugs in Central Asia and other coun-
tries worldwide can benefit from a combination of HIV-
risk reduction and economic empowerment. We expect
to see it implemented at the local and national level in
Kazakhstan, as well as in other counties in Central Asia
and globally in countries where drug use among women
is prevalent.
Trial status
Recruitment for this study began in May 2015, and the
last cohort of participants was enrolled in July 2017.
Follow-up assessments will continue through October
2018.
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